CTCF-DT: A Non-Code RNA Molecule with RNAi and RBP Regulation Potential

Target Name: CTCF-DT

NCBI ID: G107984813

CTCF-DT

Other Name(s): CTCF divergent transcript | CTD-2012K14.6 | CTD-2012K14.7

CTCF-DT: A Non-Code RNA Molecule with RNAi and RBP Regulation Potential

CTCF-DT (CTCF divergent transcript) is a molecule that has gained significant attention in the field of molecular biology due to its unique structure and bioactivity. CTCF-DT is a non-coding RNA molecule that has been shown to play a critical role in the regulation of gene expression.

The CTCF-DT molecule was first identified in the late 1990s using RNA interference (RNAi) technology. RNAi is a technique that involves using small interfering RNA (siRNA) to knockdown the expression of specific genes in a cell or organism. The CTCF-DT molecule was identified as a strong candidate for a drug target due to its ability to interact with RNAi constructs and its unique structure.

The CTCF-DT molecule has a characteristic structure that consists of a stem-loop region, a 5'-end region, and a 3'-end region. The stem-loop region is the most conserved part of the molecule and is involved in the formation of a stable double helix. The 5'-end region is the region that interacts with RNAi constructs and is involved in the formation of a stable double helix with the CTCF-DT protein. The 3'-end region is the region that interacts with the CTCF-DT protein and is involved in the formation of a stable complex.

The CTCF-DT molecule has been shown to play a critical role in the regulation of gene expression by RNAi. Studies have shown that the CTCF-DT molecule can interact with RNAi constructs and prevent their degradation. This interaction between the CTCF-DT molecule and RNAi constructs makes it a potential drug target.

In addition to its role in RNAi regulation, the CTCF-DT molecule has also been shown to play a critical role in the regulation of gene expression by other mechanisms. For example, studies have shown that the CTCF-DT molecule can interact with the protein p53 and prevent its degradation. This interaction between the CTCF-DT molecule and p53 makes it a potential biomarker for the development of cancer.

The CTCF-DT molecule has also been shown to play a critical role in the regulation of gene expression by the RNA binding protein (RBP) pathway. The RBP pathway is a protein that plays a critical role in the regulation of gene expression by binding to specific RNA molecules. Studies have shown that the CTCF-DT molecule can interact with the RBP and prevent its degradation. This interaction between the CTCF-DT molecule and RBP makes it a potential drug target for the treatment of diseases that are caused by the RBP pathway.

In conclusion, the CTCF-DT molecule is a non-coding RNA molecule that has gained significant attention in the field of molecular biology due to its unique structure and bioactivity. The CTCF-DT molecule has been shown to play a critical role in the regulation of gene expression by RNAi, the RBP pathway, and other mechanisms. As a result, the CTCF-DT molecule is a potential drug target for the treatment of diseases that are caused by the RBP pathway or RNAi regulation. Further research is needed to fully understand the unique mechanisms of the CTCF-DT molecule and its potential as a drug target.

Protein Name: CTCF Divergent Transcript

The "CTCF-DT Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CTCF-DT comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets